• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Case Reports in Nephrology and Dialysis >Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
【24h】

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report

机译：托伐普坦治疗原发性醛固酮增多症和常染色体显性遗传性多囊肾的病例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years. At the age of 58, tolvaptan was started (60 mg/day) to treat her renal disease. After 8 months of tolvaptan therapy, hypokalemia-related muscle weakness became prominent, and hypertension became refractory. Finally, treatment with low-dose tolvaptan (30 mg/day) and high-dose spironolactone (100 mg/day) normalized serum potassium and the blood pressure. Tolvaptan can induce urinary excretion of potassium in patients with primary aldosteronism, and possible mechanisms are discussed.
机译：一名59岁的日本女性因评估肌肉无力而入院。已在47岁时诊断出常染色体显性遗传性多囊肾，然后在53岁时诊断为原发性醛固酮增多症。 58岁时开始使用托伐普坦（60毫克/天）治疗其肾脏疾病。托伐普坦治疗8个月后，低钾血症相关的肌肉无力变得突出，高血压变得难治。最后，用小剂量托伐普坦（30毫克/天）和大剂量螺内酯（100毫克/天）治疗可使血清钾和血压正常化。托伐普坦可以诱导原发性醛固酮增多症患者尿中钾的排泄，并探讨了可能的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号